Perinatal EvidenceCompass
Prepopulated workbenchMED-269

Nonprescription/emerging psychoactive — cannabinoid/plant

Kava

Nonprescription anxiety/sedative exposure

Not a categorical safety rating

This record organizes questions; it does not close them.

The clinical fields and position statements are prepopulated from the public-source corpus. They have not completed individual dual extraction, formal appraisal, exact-label reconciliation, or multidisciplinary sign-off. Do not use this page to justify abrupt discontinuation or reflexive switching.

Inventory identity

What this record represents

Canonical generic name
Kava
Entity type
dietary supplement/botanical
Active component(s)
Kava
Formulation / route / interval
Oral; formulation varies
Attachment entry
Kava
Separate monograph status
No — cross-reference shared molecule monograph
Identity and cross-reference
Not populated in v0.95
Inventory verification confidence
High — direct status-changing or product-specific primary source

Decision taxonomy

Five positions kept separate

These are workbench statements for reviewer execution. They are not independently commissioned, patient-specific recommendations.

  1. 01

    Stable continuation

    Workbench statement

    Do not withhold or discontinue solely because of pregnancy or lactation. For this record, assess indication, prior response, relapse severity, dose/formulation, alternatives, exposure timing, and mapped evidence; individual commissioned adjudication remains pending.

  2. 02

    New initiation in pregnancy

    Workbench statement

    For a new start, prefer an effective option with the strongest diagnosis-specific efficacy and reproductive evidence when clinically suitable. This record has not received an individual, independently verified initiation ranking.

  3. 03

    Switch before conception

    Workbench statement

    Before conception, consider a switch only when expected benefit exceeds relapse, withdrawal, failed-switch, and dual-exposure risks. Build and monitor the plan before pregnancy when feasible; no universal switch direction is assigned here.

  4. 04

    Unplanned exposure

    Workbench statement

    After unplanned exposure, confirm product, route, dose, timing, indication, co-exposures, and symptoms; do not advise abrupt cessation. Use the mapped evidence and current label to decide whether any targeted fetal assessment is indicated.

  5. 05

    Delivery, postpartum & lactation

    Workbench statement

    Create separate delivery, postpartum-dose, neonatal-observation, and lactation plans. Do not infer breastfeeding suitability from pregnancy evidence or routinely taper before delivery without drug-specific support.

Linked evidence

3 mapped claim summaries

Mapping can include class-wide, framework, formulation, regulatory, or evidence-gap claims. A linked claim is not necessarily a drug-specific causal estimate.

C-049Provisional public source

St. John's wort, valerian, kava, ashwagandha, saffron and oral lavender lack adequate product-specific pregnancy and lactation evidence; nonpregnant extract studies do not validate retail products.

Public-source certainty descriptor
Very low product-specific certainty
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
Pregnancy and lactation
Comparator
Botanical product versus established psychiatric treatment
Effect or numbers carried forward

No adequate comparative pregnancy effectiveness data

Limitations

Species, extraction, dose, mixtures, contaminants and lot variation undermine extrapolation

Sources, citation controls, and verification state

Linked sources

PMID
28511598
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
C-050Provisional public source

St. John's wort has major CYP/P-glycoprotein and serotonergic interactions, kava has a serious liver-injury signal, and NCCIH advises avoiding ashwagandha in pregnancy and breastfeeding.

Public-source certainty descriptor
Moderate for interactions/liver signal; low reproductive outcome evidence
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
Preconception through lactation
Comparator
Use versus avoidance/established care
Effect or numbers carried forward

No pregnancy causal effect estimate

Limitations

Retail composition varies; recommendations are not based on large pregnancy cohorts

Sources, citation controls, and verification state

Linked sources

PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
C-055Provisional public source

US dietary supplements are not FDA-approved for safety and effectiveness before marketing; label identity, purity and consistency cannot be assumed.

Public-source certainty descriptor
High regulatory certainty
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
All reproductive windows
Comparator
Retail supplement versus standardized approved medicine
Effect or numbers carried forward

Not applicable

Limitations

Some products follow quality programs, but that does not establish pregnancy effectiveness or safety

Sources, citation controls, and verification state

Linked sources

PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending